Lynn G Dressler

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. doi request reprint Return of research results from pharmacogenomic versus disease susceptibility studies: what's drugs got to do with it?
    Lynn G Dressler
    University of North Carolina, Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, Institute of Pharmacogenomics and Individualized Therapy, 120 Mason Farm Rd, Genetic Medicine Building, Rm 1091, CB7361, Chapel Hill, NC 27599 7361, USA
    Pharmacogenomics 13:935-49. 2012
  2. pmc IRB perspectives on the return of individual results from genomic research
    Lynn G Dressler
    Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, USA
    Genet Med 14:215-22. 2012
  3. doi request reprint Disclosure of research results from cancer genomic studies: state of the science
    Lynn G Dressler
    University of North Carolina School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill, North Carolina, USA
    Clin Cancer Res 15:4270-6. 2009
  4. ncbi request reprint Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients
    Lynn G Dressler
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7295, Mason Farm Rd, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 23:4287-97. 2005
  5. ncbi request reprint Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
  6. pmc Epidemiology of basal-like breast cancer
    Robert C Millikan
    Department of Epidemiology, CB 7435, School of Public Health, University of North Carolina, Chapel Hill, NC 27599 7435, USA
    Breast Cancer Res Treat 109:123-39. 2008
  7. pmc Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study
    Katie M O'Brien
    Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Clin Cancer Res 16:6100-10. 2010
  8. ncbi request reprint Mutation of GATA3 in human breast tumors
    Jerry Usary
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Oncogene 23:7669-78. 2004
  9. doi request reprint Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care
    Tejinder K Rakhra-Burris
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7361, USA
    Pharmacogenomics 11:13-21. 2010

Detail Information

Publications9

  1. doi request reprint Return of research results from pharmacogenomic versus disease susceptibility studies: what's drugs got to do with it?
    Lynn G Dressler
    University of North Carolina, Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, Institute of Pharmacogenomics and Individualized Therapy, 120 Mason Farm Rd, Genetic Medicine Building, Rm 1091, CB7361, Chapel Hill, NC 27599 7361, USA
    Pharmacogenomics 13:935-49. 2012
    ..This article evaluates and compares the return of individual research results from disease susceptibility studies versus pharmacogenomic studies...
  2. pmc IRB perspectives on the return of individual results from genomic research
    Lynn G Dressler
    Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, USA
    Genet Med 14:215-22. 2012
    ..However, the perspective of key stakeholders-institutional review board (IRB) professionals-has been missing from this dialogue. This study explores the positions and experiences of IRB members and staff regarding this issue...
  3. doi request reprint Disclosure of research results from cancer genomic studies: state of the science
    Lynn G Dressler
    University of North Carolina School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill, North Carolina, USA
    Clin Cancer Res 15:4270-6. 2009
    ..These assessments, along with what is considered useful information, requires the involvement of the research subject community to inform decision-making and move the policy process forward...
  4. ncbi request reprint Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients
    Lynn G Dressler
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7295, Mason Farm Rd, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 23:4287-97. 2005
    ....
  5. ncbi request reprint Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
    ..Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B...
  6. pmc Epidemiology of basal-like breast cancer
    Robert C Millikan
    Department of Epidemiology, CB 7435, School of Public Health, University of North Carolina, Chapel Hill, NC 27599 7435, USA
    Breast Cancer Res Treat 109:123-39. 2008
    ..Among younger African-American women, we estimate that up to 68% of basal-like breast cancer could be prevented by promoting breastfeeding and reducing abdominal adiposity...
  7. pmc Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study
    Katie M O'Brien
    Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Clin Cancer Res 16:6100-10. 2010
    ....
  8. ncbi request reprint Mutation of GATA3 in human breast tumors
    Jerry Usary
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Oncogene 23:7669-78. 2004
    ..These data suggest that GATA3 is involved in growth control and the maintenance of the differentiated state in epithelial cells, and that GATA3 variants may contribute to tumorigenesis in ESR1-positive breast tumors...
  9. doi request reprint Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care
    Tejinder K Rakhra-Burris
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7361, USA
    Pharmacogenomics 11:13-21. 2010
    ..IPIT Investigators are actively incorporating a pharmacogenomics curriculum into existing teaching programs at all levels...